Abstract
Between 1990 and 1996, three patients (1.1%), all with CML, among 272 patients with haematological malignancies, developed bilateral subdural haematomas (SDH) after treatment with i.t. MTX before HSCT in our unit. Since October 1996, we have given i.t. MTX only to patients at increased risk of CNS leukaemia such as ALL and AML M4 or M5. We suggest that intrathecal treatment before HSCT should only be given to patients at increased risk of CNS leukaemia.
MeSH terms
-
Adult
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / adverse effects
-
Hematoma, Subdural / diagnostic imaging
-
Hematoma, Subdural / etiology*
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Risk Factors
-
Spinal Puncture / adverse effects*
-
Tomography, X-Ray Computed
Substances
-
Antimetabolites, Antineoplastic
-
Methotrexate